Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production

[1]  A. Laupacis,et al.  COX-2 inhibitors and risk of heart failure , 2004, The Lancet.

[2]  P. Wong,et al.  Association of γ-Secretase with Lipid Rafts in Post-Golgi and Endosome Membranes* , 2004, Journal of Biological Chemistry.

[3]  A. Nadin,et al.  Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site , 2004, Journal of Biological Chemistry.

[4]  B. Hyman,et al.  Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation , 2004, Nature Medicine.

[5]  C. Martínez-A,et al.  Statins Inhibit HIV-1 Infection by Down-regulating Rho Activity , 2004, The Journal of experimental medicine.

[6]  Ann-Shyn Chiang,et al.  Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer's disease , 2004 .

[7]  R. DuBois,et al.  COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.

[8]  J. Shioi,et al.  Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[9]  Valentina Gelfanova,et al.  Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß42 by Inhibiting Rho , 2003, Science.

[10]  S. Weggen,et al.  The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 Production* , 2003, Journal of Biological Chemistry.

[11]  S. Weggen,et al.  Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[12]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[13]  T. Iwatsubo,et al.  Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation* , 2003, The Journal of Biological Chemistry.

[14]  L. Marlow,et al.  Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme* , 2003, The Journal of Biological Chemistry.

[15]  J. Najib.  Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. , 2002, Clinical therapeutics.

[16]  J. Liao.  Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[17]  C. Meinert,et al.  Double placebo design in a prevention trial for Alzheimer's disease. , 2002, Controlled clinical trials.

[18]  S. Younkin,et al.  Cholesterol-Dependent γ-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains , 2002, Neurobiology of Disease.

[19]  Gaochao Zhou,et al.  Dual Mechanisms of ABCA1 Regulation by Geranylgeranyl Pyrophosphate* , 2001, The Journal of Biological Chemistry.

[20]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[21]  M. Mercken,et al.  A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2001, Neurobiology of Disease.

[22]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[23]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[24]  Robert A. Copeland,et al.  Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors* , 2000, The Journal of Biological Chemistry.

[25]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[26]  Yi Zheng,et al.  Inhibition of RhoA by p120 catenin , 2000, Nature Cell Biology.

[27]  P. Fraser,et al.  Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage. , 2000, The Journal of biological chemistry.

[28]  S. Younkin,et al.  Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease , 2000 .

[29]  L. Marnett,et al.  Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. , 2000, Journal of medicinal chemistry.

[30]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[31]  N. Davies,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib , 2000, Clinical pharmacokinetics.

[32]  L. Marnett,et al.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Holzinger,et al.  The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. , 1999, European journal of biochemistry.

[34]  C. Marshall,et al.  New Insights into the Interaction of Ras with the Plasma Membrane , 1999, Cell.

[35]  S. Younkin.  The role of Aβ42 in Alzheimer's disease , 1998, Journal of Physiology-Paris.

[36]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Gandy,et al.  The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. , 1996, The Journal of biological chemistry.

[38]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[39]  R. Keller,et al.  Squalene synthase inhibition alters metabolism of nonsterols in rat liver. , 1996, Biochimica et biophysica acta.

[40]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[41]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[42]  F. Oesch,et al.  Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver , 1992, FEBS letters.

[43]  P. Wong,et al.  Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. , 2004, The Journal of biological chemistry.

[44]  T. Iwatsubo,et al.  Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. , 2003, The Journal of biological chemistry.

[45]  J. Shioi,et al.  Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. , 2003, The Journal of biological chemistry.

[46]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.

[47]  S. Weggen,et al.  The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. , 2003, The Journal of biological chemistry.

[48]  S. Weggen,et al.  Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. , 2003, The Journal of biological chemistry.

[49]  F. Liu,et al.  Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. , 2003, Science.

[50]  S. Younkin,et al.  Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. , 2002, Neurobiology of disease.

[51]  D. Teplow,et al.  Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. , 2002, Gene expression.

[52]  宮田 健二.  Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo , 2001 .

[53]  津川 康治.  A selective cyclo-oxygenase-2 inhibitor,NS-398,may improve portal hypertension without inducing gastric mucosal injury , 2001 .

[54]  S. Younkin,et al.  Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. , 2000, Biochimica et biophysica acta.

[55]  M. Schwartz,et al.  Determination of GTP loading on Rho. , 2000, Methods in enzymology.

[56]  S. Younkin.  The role of A beta 42 in Alzheimer's disease. , 1998, Journal of physiology, Paris.

[57]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[58]  T. Golde,et al.  The FASEB Journal express article 10.1096/fj.00-0286fje. Published online October 6, 2000. Cell-free assays for γ-secretase activity , 2022 .